COLUMBIA, Md., May 21 Martek BiosciencesCorporation (Nasdaq: MATK) announced today that it will be presenting at the2008 UBS Global Generic and Specialty Pharmaceuticals Conference in London.The conference is being held May 28 -- 29, 2008 at the Waldorf Hilton,Aldwych, London. Steve Dubin, CEO will be presenting on Wednesday, May 28,2008 at 9:00 a.m. EDT (2:00 p.m. London Time).
Interested parties may access a live audio webcast of Martek'spresentation through the UBS website at:http://www.ibb.ubs.com/Conferences/co_highlights.shtml
Martek Biosciences Corporation (Nasdaq: MATK) is a leader in theinnovation and development of DHA omega-3 products that promote health andwellness through every stage of life. The company produces life'sDHA(TM), asustainable and vegetarian source of the omega-3 fatty acid DHA(docosahexaenoic acid), for use in foods, beverages, infant formula, andsupplements. The company also produces life'sARA(TM) (arachidonic acid), anomega-6 fatty acid, from a sustainable, vegetarian source, for use in infantformula. For more information on Martek Biosciences Corporation, visithttp://www.martek.com.
Contact: Kyle StultsInvestor Relations (410) 740-0081
SOURCE Martek Biosciences Corporation